Assessing Bio-Techne (TECH) Valuation After Mixed Recent Share Performance

What recent performance tells you about Bio-Techne

Bio-Techne (TECH) has seen mixed share performance recently, with gains of 1.9% over the past day and 2.6% over the past week, set against declines over the month and past 3 months.

See our latest analysis for Bio-Techne.

At a share price of US$59.0, Bio-Techne’s recent 1-day and 7-day share price gains come after a 1-year total shareholder return decline of 3.9% and a 5-year total shareholder return decline of 32.3%. This suggests short-term momentum, while longer-term performance has been weaker.

If this mixed picture has you looking beyond a single stock, it could be a good moment to check out our screener of 27 healthcare AI stocks as another way to find ideas in a similar space.

So with Bio-Techne trading at US$59.0 and showing an estimated intrinsic discount alongside a gap to analyst targets, is the recent weakness setting up a potential entry point, or is the market already pricing in future growth?

Most Popular Narrative: 21.6% Undervalued

At a last close of $59.0 versus a narrative fair value of $75.25, the widely followed view on Bio-Techne points to meaningful upside being modeled.

The analysts have a consensus price target of $66.231 for Bio-Techne based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $75.0, and the most bearish reporting a price target of just $53.0.

Read the complete narrative.

Curious what justifies a higher fair value than the consensus target range? The narrative attributes this to steady revenue expansion, rising margins, and a richer future earnings multiple. The exact mix of those three inputs is where the story becomes more detailed.

Result: Fair Value of $75.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on biotech and NIH funding not tightening further, and on geopolitical or tariff pressures not weighing more heavily on key pharma customers.

Find out about the key risks to this Bio-Techne narrative.

Another View: P/E Ratios Flash A Caution Sign

While the narrative and our own cash flow work point to Bio-Techne trading around 18.7% below fair value, the simple P/E check tells a very different story. At 113.9x earnings versus a 34.9x industry average and a 23.4x peer average, the stock sits far above its reference points.

The fair ratio of 25.2x is also far below the current 113.9x, which means the market would need to compress the multiple sharply to line up with that benchmark. For you as an investor, the question is whether cash flow strength ultimately wins out, or rich earnings multiples start to matter more.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and earnings multiples, it is worth seeing the numbers for yourself and deciding where you stand, especially as our work highlights both risks and rewards, including 3 key rewards and 2 important warning signs.

Ready for more investment ideas?

If this story has sharpened your thinking, do not stop here. Widening your watchlist with fresh ideas can be just as important as analyzing one stock closely.

• Target potential value opportunities by scanning our list of 46 high quality undervalued stocks, built from companies with pricing that stands out against their fundamentals.
• Prioritize resilience by checking out 77 resilient stocks with low risk scores, focusing on businesses our model flags with relatively lower overall risk scores.
• Broaden your horizons with screener containing 24 high quality undiscovered gems, a collection of smaller names that meet strict quality and fundamentals filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com